RxDoctor Payments Data

Ashish Chaddha, MD

Interventional Cardiology · Milwaukee, WINPI 1376955492

Payments from drug & device makers

$4,505in general payments, 2019–2025

Across 143 payments — averaging $31.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Medtronic$1K
  • Boston Scientific$688
  • Novartis$344
  • E.r. Squibb & Sons, L.L.C.$190
  • Merck$138
  • plus $805 from 14 others

What the payments were for

  • Travel & lodging$1,41431%
  • Food & beverage$3,09169%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,505 in reported general payments places this provider in the 45th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$185,378
Medicare patients
1,337
Services billed
3,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$301,647
EntrestoSacubitril/Valsartan55$57,923
Repatha SureclickEvolocumab72$49,416
XareltoRivaroxaban47$43,025
BrilintaTicagrelor40$31,883
FarxigaDapagliflozin Propanediol38$31,025
JardianceEmpagliflozin17$14,445
VascepaIcosapent Ethyl24$11,919
Praluent PenAlirocumab14$9,168
Rosuvastatin Calcium517$7,742
Metoprolol Succinate388$5,626
Icosapent Ethyl23$4,551
Isosorbide Dinitrate13$3,575
Ranolazine ErRanolazine31$3,417
Ezetimibe137$3,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$301,647318 claims
AstraZenecaBrilinta, Farxiga$27$62,90878 claims
NovartisEntresto$344$57,92355 claims
Johnson & JohnsonXarelto$115$43,02547 claims
Boehringer IngelheimJardiance$17$14,44517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →